This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
SYAB Overzicht aandelen
Provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
SYNLAB AG Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €11.04 |
| 52 Week Hoogtepunt | €12.30 |
| 52 Week Laag | €8.02 |
| Bèta | 0.89 |
| 11 maand verandering | 0% |
| 3 maanden verandering | -0.72% |
| 1 Jaar Verandering | 25.53% |
| 33 jaar verandering | -46.82% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -44.03% |
Recent nieuws en updates
Recent updates
SYNLAB (FRA:SYAB) Might Have The Makings Of A Multi-Bagger
Dec 15
Returns Are Gaining Momentum At SYNLAB (FRA:SYAB)
Sep 10SYNLAB AG (FRA:SYAB) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 14SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market
May 29SYNLAB (FRA:SYAB) Is Investing Its Capital With Increasing Efficiency
May 20Are Investors Undervaluing SYNLAB AG (FRA:SYAB) By 25%?
Sep 26Shareholders Will Be Pleased With The Quality of SYNLAB's (FRA:SYAB) Earnings
Aug 22Rendement voor aandeelhouders
| SYAB | DE Healthcare | DE Markt | |
|---|---|---|---|
| 7D | 0% | -1.5% | 0.8% |
| 1Y | 25.5% | 23.5% | 14.0% |
Rendement versus industrie: SYAB exceeded the German Healthcare industry which returned 4.6% over the past year.
Rendement versus markt: SYAB exceeded the German Market which returned 6.7% over the past year.
Prijsvolatiliteit
| SYAB volatility | |
|---|---|
| SYAB Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 3.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stabiele aandelenkoers: SYAB has not had significant price volatility in the past 3 months.
Volatiliteit in de loop van de tijd: Insufficient data to determine SYAB's volatility change over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1998 | 27,000 | Mathieu Floreani | www.synlab.com |
SYNLAB AG Samenvatting
| SYAB fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €2.43b |
| Inkomsten(TTM) | €89.35m |
| Inkomsten(TTM) | €2.62b |
27.2x
Koers/Winstverhouding0.9x
P/S-verhoudingIs SYAB overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| SYAB resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €2.62b |
| Kosten van inkomsten | €604.92m |
| Brutowinst | €2.01b |
| Overige uitgaven | €1.92b |
| Inkomsten | €89.35m |
Laatst gerapporteerde inkomsten
Mar 31, 2024
Volgende inkomensdatum
Nov 07, 2024
| Winst per aandeel (EPS) | 0.41 |
| Brutomarge | 76.87% |
| Nettowinstmarge | 3.42% |
| Schuld/Eigen Vermogen Verhouding | 39.0% |
Hoe presteerde SYAB op de lange termijn?
Bekijk historische prestaties en vergelijking